Muscarinic receptor subtypes in human nasal mucosa: characterization, autoradiographic localization, and function in vitro. 1993

M Okayama, and J Mullol, and J N Baraniuk, and J N Hausfeld, and B Feldman, and M Merida, and J H Shelhamer, and M A Kaliner
First Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.

Muscarinic receptors play important roles in the regulation of glandular secretion and vasomotor tone in human nasal mucosa. M1, M2, and M3 muscarinic receptor subtypes were pharmacologically characterized in human inferior turbinates by receptor-binding assays using [3H](-)quinuclidinyl benzilate (QNB, identifies total muscarinic receptors) and [3H]-pirenzepine (PZ). Receptors were localized by autoradiography, and their function examined in vitro by assaying mucus secretion from cultured nasal mucosal explants. In competition assays, PZ was employed as a selective muscarinic antagonist for M1 receptors, gallamine and AF-DX 116 for M2 receptors, and 4-DAMP for M3 receptors. These ligands are selective at low nanomolar concentrations, but can interact with other muscarinic receptors at higher concentrations. It is not known if they can interact with putative M4 and M5 muscarinic receptor subtypes. Using [3H](-)QNB, total muscarinic receptor binding was 688.4 +/- 49.6 fmol/mg protein (Bmax), with a Kd of 1.47 +/- 0.13 nM. [3H]-PZ bound to 45% of the total QNB binding sites. In competition experiments, 4-DAMP displaced [3H](-)QNB with the lowest IC50, followed by PZ and AF-DX 116. Autoradiograms demonstrated that [3H](-)QNB binding was completely displaced by 4-DAMP, partially displaced by PZ, but not displaced by gallamine or AF-DX 116, and suggested that M1 and M3 subtypes coexist in submucosal glands. The localization of M1 receptors on submucosal glands was confirmed by direct labeling with [3H]-PZ. [3H]-PZ also labeled vessels, but with a low silver grain density. Autoradiographic [3H]-QNB binding was displaced by 4-DAMP and atropine, but not by PZ, gallamine, or AF-DX 116. In studies of mucus secretion in vitro, 4-DAMP significantly inhibited methacholine-induced secretion. Although less effective, PZ also had significant inhibitory effects. Neither gallamine nor AF-DX 116 had any inhibitory effect. M1 receptors (PZ binding sites) may regulate glandular secretion while M3 receptors (4-DAMP binding sites) may regulate glandular secretion and vasomotor tone in human nasal mucosa.

UI MeSH Term Description Entries
D009831 Olfactory Mucosa That portion of the nasal mucosa containing the sensory nerve endings for SMELL, located at the dome of each NASAL CAVITY. The yellow-brownish olfactory epithelium consists of OLFACTORY RECEPTOR NEURONS; brush cells; STEM CELLS; and the associated olfactory glands. Olfactory Epithelium,Olfactory Membrane,Epithelium, Olfactory,Membrane, Olfactory,Membranes, Olfactory,Mucosa, Olfactory,Olfactory Membranes
D010890 Pirenzepine An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients. Gastrotsepin,Gastrozepin,L-S 519,LS-519,Piren-Basan,Pirenzepin,Pirenzepin Von Ct,Pirenzepin-Ratiopharm,Pirenzepine Dihydrochloride,Pyrenzepine,Ulcoprotect,Ulgescum,Dihydrochloride, Pirenzepine,LS 519,LS519,Piren Basan,Pirenzepin Ratiopharm,Von Ct, Pirenzepin
D011813 Quinuclidinyl Benzilate A high-affinity muscarinic antagonist commonly used as a tool in animal and tissue studies. Benzilate, Quinuclidinyl
D011869 Radioligand Assay Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). Protein-Binding Radioassay,Radioreceptor Assay,Assay, Radioligand,Assay, Radioreceptor,Assays, Radioligand,Assays, Radioreceptor,Protein Binding Radioassay,Protein-Binding Radioassays,Radioassay, Protein-Binding,Radioassays, Protein-Binding,Radioligand Assays,Radioreceptor Assays
D011976 Receptors, Muscarinic One of the two major classes of cholinergic receptors. Muscarinic receptors were originally defined by their preference for MUSCARINE over NICOTINE. There are several subtypes (usually M1, M2, M3....) that are characterized by their cellular actions, pharmacology, and molecular biology. Muscarinic Acetylcholine Receptors,Muscarinic Receptors,Muscarinic Acetylcholine Receptor,Muscarinic Receptor,Acetylcholine Receptor, Muscarinic,Acetylcholine Receptors, Muscarinic,Receptor, Muscarinic,Receptor, Muscarinic Acetylcholine,Receptors, Muscarinic Acetylcholine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001345 Autoradiography The making of a radiograph of an object or tissue by recording on a photographic plate the radiation emitted by radioactive material within the object. (Dorland, 27th ed) Radioautography
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding
D046508 Culture Techniques Methods of maintaining or growing biological materials in controlled laboratory conditions. These include the cultures of CELLS; TISSUES; organs; or embryo in vitro. Both animal and plant tissues may be cultured by a variety of methods. Cultures may derive from normal or abnormal tissues, and consist of a single cell type or mixed cell types. Culture Technique,Technique, Culture,Techniques, Culture

Related Publications

M Okayama, and J Mullol, and J N Baraniuk, and J N Hausfeld, and B Feldman, and M Merida, and J H Shelhamer, and M A Kaliner
January 1993, Progress in brain research,
M Okayama, and J Mullol, and J N Baraniuk, and J N Hausfeld, and B Feldman, and M Merida, and J H Shelhamer, and M A Kaliner
May 1998, Neuroscience letters,
M Okayama, and J Mullol, and J N Baraniuk, and J N Hausfeld, and B Feldman, and M Merida, and J H Shelhamer, and M A Kaliner
June 1990, The American review of respiratory disease,
M Okayama, and J Mullol, and J N Baraniuk, and J N Hausfeld, and B Feldman, and M Merida, and J H Shelhamer, and M A Kaliner
May 1984, European journal of pharmacology,
M Okayama, and J Mullol, and J N Baraniuk, and J N Hausfeld, and B Feldman, and M Merida, and J H Shelhamer, and M A Kaliner
January 1988, Life sciences,
M Okayama, and J Mullol, and J N Baraniuk, and J N Hausfeld, and B Feldman, and M Merida, and J H Shelhamer, and M A Kaliner
November 2006, Journal of endourology,
M Okayama, and J Mullol, and J N Baraniuk, and J N Hausfeld, and B Feldman, and M Merida, and J H Shelhamer, and M A Kaliner
January 1986, Brain research,
M Okayama, and J Mullol, and J N Baraniuk, and J N Hausfeld, and B Feldman, and M Merida, and J H Shelhamer, and M A Kaliner
July 2002, The Annals of otology, rhinology, and laryngology,
M Okayama, and J Mullol, and J N Baraniuk, and J N Hausfeld, and B Feldman, and M Merida, and J H Shelhamer, and M A Kaliner
September 2007, Rhinology,
M Okayama, and J Mullol, and J N Baraniuk, and J N Hausfeld, and B Feldman, and M Merida, and J H Shelhamer, and M A Kaliner
February 1988, Trends in pharmacological sciences,
Copied contents to your clipboard!